Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)

NCT07714317 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Resectable Hepatocellular Carcinoma

Interventions

DRUG: IBI310+ sintilimab + bevacizumab
DRUG: IBI310+ sintilimab
DRUG: sintilimab + bevacizumab

Sponsor

Shanghai Zhongshan Hospital